Stamford, CT -- (SBWIRE) -- 05/01/2013 -- Jet Life Penny Stocks provides investors with the Best penny stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with the goal of keeping you loyal to our service. Our today’s focus is on: - Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Onyx Pharmaceuticals Inc. (ONXX), Gilead Sciences, Inc (NASDAQ:GILD), ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC)
Biotechnology industry performed well on Tuesday trading session and ended the session with positive change of +0.03%.
Aveo Pharmaceuticals Inc. (NASDAQ:AVEO)’s top product candidate, a kidney cancer drug, might require another clinical trial to evaluate the benefit, US controllers reported. Aveo shares declined in early session.
Can Investors Bet on AVEO after this News update? Find out in this Research Report
While the medicine indicated superior results than Bayer AG (BAYN) and Onyx Pharmaceuticals Inc. (ONXX)’s Nexavar in postponing disease progression, a trend toward a lowering in patients’ overall survival led Food and Drug Administration staff in a report on Tuesday to question whether Aveo should conduct further study. A panel of FDA advisers would meet May 2 to talk about the compound, named tivozanib.
Gilead Sciences, Inc (NASDAQ:GILD) witnessed two consecutive delays when the US Food and Drug Administration (:FDA) issued complete response letters (CRLs) to the firm’s HIV candidates, elvitegravir and cobicistat, for use as an element of HIV therapy regimens.
Is GILD a Solid Investment at These Levels? Read This Report For Details
We stated that Gilead is looking for acceptance of elvitegravir for use in treatment-experienced HIV patients. Cobicistat works as a “boosting” agent whose addition causes blood levels of protease inhibitors to hike, thereby letting the HIV therapy to be dosed once daily.
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) on Tuesday declared that it intends to announce first quarter 2013 financial earnings on Thursday, May 9, 2013.
How Should Investors Trade IMUC Now? Don’t Miss out a Special Trend Analysis
ImmunoCellular would host a conference call and webcast to talk about financial earnings and give a business update at 5:00 p.m. ET that day. The call would be hosted by Andrew Gengos, President and CEO.
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Jet Life Penny Stocks also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)